HR 7050 would end the FDA's long-standing enforcement discretion over homeopathic products and require individual pre-market approval for each product. For CHD, PG, and CLX, the affected product lines represent a small fraction of total revenue. The bill is at the earliest legislative stage and faces a long path to enactment. Market data shows no pricing of this risk: CHD is up 4.02% in 30 days, PG up 1.86%, CLX down 7.02% due to unrelated factors.
→ Compliance with new FDA approval pathway imposes costs exceeding economic value for most existing homeopathic products, forcing discontinuation of product lines. No grandfathering or transition period is specified in bill text beyond standard effective dates.
HR7050